[ CancerWeb Home
| Comments
| Up One Level ]
Original Summaries of Selected CANCERLIT Records
Percent Change in PSA as a Prostate Cancer Marker
Last modified on:
Tuesday, April 20, 1999 10:52:30
Copyright © 1994-2008, Information Ventures, Inc.
Markers serve not only for screening and overall prognosis, but
also to monitor response to therapy, residual disease, and
likelihood of a recurrence. Post-therapy decline in PSA is the at
present the most significant predictor of survival in patients with
androgen independent prostate cancer. A group from John Hopkins
Oncology Center, Baltimore (Eisenberger; ICDB/95/13766) reported on
a study carried out from 1989 to 1994 with 1387 stage D2 prostate
cancer patients. PSA (ng/ml) determinations were obtained
pre-prescription, day 30 and every 3 months but not used to
determine protocol treatment. Of the first 500 patients
registered, 282 are now fully evaluable for analysis of PSA., with
a median follow-up time of 463 days. Median baseline PSA is 166
ng/ml (4.3-14,721), and median baseline log (base 10) PSA 2.2
(0.6-4.2). Of 282 patients, 213 (76%) had a PSA decrease to less
than or equal to 4.0 ng/ml (92% for minimal and 70% for severe
disease, p less than 0.001). The percent decrease in log PSA was
the strongest predictor of survival (p=0.0005), prevailing over
other pretreatment prognostic parameters. As a result of these
findings, percent change in log PSA will be evaluated as a
surrogate marker in the context of protocol INT-0105.
November, 1995
Copyright (c) 1994-2008, Information Ventures, Inc.
Mail us at: Customer-Service@infoventures.com
http://infoventures.com